Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On November 29, 2022, Aspira Women's Health Inc. (the "Company") received a
written notice (the "Notice") from the Listing Qualifications Department (the
"Staff") of the Nasdaq Stock Market ("Nasdaq") that the Company has been granted
an additional 180 calendar days, or until May 29, 2023 (as the first trading day
following such period), to regain compliance with the minimum closing bid price
of $1.00 per share, as is required for continued listing on The Nasdaq Capital
Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement").
As the Company previously reported on that certain Current Report on Form 8-K
filed on June 2, 2022 with the U.S. Securities and Exchange Commission, on June
1, 2022, the Company received a deficiency letter (the "Initial Notice") from
the Staff notifying the Company that, for the preceding 30 consecutive business
days, the Company had not been in compliance with the Bid Price Requirement. In
accordance with Nasdaq rules, the Company was provided an initial period of 180
calendar days, or until November 28, 2022 (the "Initial Compliance Date"), to
regain compliance with the Bid Price Requirement. The Initial Notice also
provided that the Company may be eligible for an additional 180 calendar day
compliance period if it provided a written notice to Nasdaq of its intent to
cure such deficiency.
As the Company did not regain compliance with the Bid Price Requirement by the
Initial Compliance Date, the Company applied for an extension of the cure
period, as permitted under the Initial Notice. The Staff granted the Company
such extension of the cure period because (i) the Company has indicated that, to
the extent necessary, it intends to cure the deficiency by effecting a reverse
stock split and (ii) the Company meets the continued listing requirement for the
market value of publicly held shares and all other initial listing standards for
The Nasdaq Capital Market, with the exception of the Bid Price Requirement.
According to the Notice, if at any time before May 29, 2023 the closing bid
price for the Company's common stock is at least $1.00 per share for a minimum
of 10 consecutive business days (or in excess of ten consecutive business days,
if determined at the discretion of the Staff in accordance with Nasdaq Listing
Rule 5810(c)(3)), the Staff will provide written confirmation of compliance with
the Bid Price Requirement and the common stock will continue to be eligible for
listing on The Nasdaq Capital Market.
If the Company does not regain compliance with the Bid Price Requirement by May
29, 2023, the Staff will provide a written notification to the Company that its
common stock will be subject to delisting. At that time, the Company may appeal
the Staff's delisting determination to a Nasdaq Hearing Panel (the "Panel"). The
Company expects that its common stock would remain listed pending the Panel's
decision. There can be no assurance that the Company will regain compliance or
otherwise maintain compliance with any of the other listing requirements.
?
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ASPIRA WOMEN'S HEALTH INC. 
